Clinical Trial Update: Irinotecan Liposome II in Combination With 5-FU/LV and Oxaliplatin in Perioperative Treatment of Borderline Resectable Pancreatic Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating irinotecan liposome II in combination with 5-FU/leucovorin and oxaliplatin for perioperative treatment of borderline resecta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Borderline Resectable Pancreatic Cancer

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Irinotecan Liposome II (irinotecan liposome)
• Leucovorin (folinic acid)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Borderline Resectable Pancreatic Cancer | Phase 2 | Status: RECRUITING